aTyr Pharma
ATYR
40 hedge funds and large institutions have $58.7M invested in aTyr Pharma in 2023 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 6 increasing their positions, 18 reducing their positions, and 8 closing their positions.
513% more call options, than puts
Call options by funds: $49K | Put options by funds: $8K
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
1.35% less ownership
Funds ownership: 65.7% → 64.35% (-1.3%)
2% less funds holding
Funds holding: 41 → 40 (-1)
13% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 8
24% less capital invested
Capital invested by funds: $77M → $58.7M (-$18.4M)
67% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 18
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$2.71M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$765K |
| 3 |
TCM
Tang Capital Management
San Diego,
California
|
+$594K |
| 4 |
Alyeska Investment Group
Chicago,
Illinois
|
+$463K |
| 5 |
PFCS
Pale Fire Capital SE
Prague,
Czech Republic
|
+$103K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Investments
New York
|
-$607K |
| 2 |
Man Group
London,
United Kingdom
|
-$568K |
| 3 |
Millennium Management
New York
|
-$496K |
| 4 |
Two Sigma Advisers
New York
|
-$351K |
| 5 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$179K |
ATYR Hedge Fund Activity: Q3 2023 in Review
40 of the 6,310 institutional investors tracked by Wall St. Rank reported a position in aTyr Pharma (ATYR) for Q3 2023, worth a combined $58.7M — down 24% from $77M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of ATYR and 7 opened new positions — a net loss of 1 holder — while 18 trimmed existing stakes and 6 added.
The largest buyer was Citadel Advisors, adding an estimated $2.71M. The largest seller was Two Sigma Investments, cutting an estimated $607K.
- 40 institutional investors held aTyr Pharma (ATYR) as of Q3 2023, down from 41 in Q2 2023.
- Funds reported $58.7M of aTyr Pharma stock for Q3 2023, down 24% quarter-over-quarter.
- 7 funds opened new aTyr Pharma positions in Q3 2023 and 8 closed out, a net change of -1 holder.
- The largest aTyr Pharma buyer in Q3 2023 was Citadel Advisors, an estimated $2.71M added.
- The largest aTyr Pharma seller in Q3 2023 was Two Sigma Investments, an estimated $607K sold.
Based on aggregated 13F filings for Q3 2023.